MWMikaela M. Weeder

Mikaela M. Weeder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mikaela M. Weeder has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacokinetic Parameters of Oral Firocoxib, Oral Meloxicam, and Transdermal Flunixin in Meat Type Goats

    by Mikaela M. Weeder, Michael D. Kleinhenz, Christopher T. Culbertson, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Misty Bear, Andrew K. Curtis, Ally A. Nelson, Bailey R. Fritz, et al.

    The objective of this study was to determine and compare the pharmacokinetics of oral firocoxib, oral meloxicam, and transdermal flunixin (TD) in 44 adult, male castrated, crossbred goats. Pharmacokinetic (PK) analysis was performed for each goat in each phase using non‐compartmental methods with descriptive statistics reported. Mean plasma half‐life (T 1/2 (h)) for oral (PO) administration of firocoxib at varying dosages in meat type castrated goats was reported at 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg at 9.1 (range 6.9–13.4), 10.2 (range 6.4–14.7) and 9.2 (range 6.8–12.8), respectively. For oral meloxicam, mean plasma T 1/2 at doses of 1.0 mg/kg, 2.0 mg/kg, and 3.0 mg/kg were 13.3 (range: 10.1–22.3), 13.1 (range: 12–24), and 11.7 (range: 8.3–20.5) hours, respectively. Transdermal flunixin showed mean plasma T 1/2 of 16.5 (range: 10.7–62) at 3.3 mg/kg, 22.0 (range: 16.6–67.4) at 4.2 mg/kg, and 17.8 (range: 7.4–56.3) at 5.0 mg/kg. These results highlight significant variability in drug disposition and suggest that further research is warranted to optimize dosing regimens for oral firocoxib, oral meloxicam, and transdermal flunixin in goats.

  • Open Access

    Comparison of multiple drug regimens for reduction of synovitis-induced lameness pain in meat-type goats

    by Mikaela M. Weeder, Michael D. Kleinhenz, Emily J. Reppert, Andrew K. Curtis, Abbie V. Viscardi, Ally Leslie, Misty Bear, Bailey Fritz, Payton Dahmer, Johann F. Coetzee

    Objective: This study evaluated the analgesic effects of firocoxib, meloxicam, and transdermal flunixin in meat-type goats with experimentally induced lameness. Methods: 44 crossbred castrated meat-type goats with an average weight of 35 kg (range, 25 to 43 kg) were enrolled from June to December 2022. Lameness was induced with amphotericin B injected in the distal interphalangeal joint of the left hind lateral claw. After a washout period, lameness was reproduced in the right hind limb. Eleven treatment groups were implemented: firocoxib (0.5, 1.0, and 2.0 mg/kg), meloxicam (1.0, 2.0, and 3.0 mg/kg, transdermal flunixin (3.3, 4.2, and 5.0 mg/kg), and positive and negative control. Outcome measurements included infrared thermography, mechanical nociception threshold, plasma cortisol, plasma substance P, kinetic gait analysis, visual lameness scoring, and visual analog scoring and were collected at –24, 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours relative to lameness induction. Results: Transdermal flunixin at 3.3 and 5.0 mg/kg demonstrated the greatest analgesic effects from outcome measurements collected. Conclusions: Transdermal flunixin meglumine provides the most effective analgesia for goats with induced lameness, suggesting it may be the preferred option for pain relief in goats with lameness symptoms. Clinical Relevance: Transdermal flunixin meglumine at 3.3 or 5.0 mg/kg provided the best results for pain mitigation in goats with induced lameness.


  • Open Access

    Evaluation of oral meloxicam in beef calves with neonatal calf diarrhea

    by Hannah M. Neill, Emily J. Reppert, Michael D. Kleinhenz, Mikaela M. Weeder, Dane Schwartz, Misty Bear, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee, Abbie V. Viscardi

    Objective: To examine behavioral and physiologic outcomes associated with the expression of pain in calves with naturally occurring neonatal calf diarrhea (NCD) and determine the impact of meloxicam administration on reducing these pain-related behaviors and outcomes. Methods: Beef calves 3 to 30 days old with NCD and no comorbidities or prior NSAID or steroid administration were enrolled as clinical cases, and healthy beef calves were enrolled as controls. Clinical cases received either meloxicam (MEL group) or placebo (PLBO group) treatment; all controls received placebo. Over 7 time points, outcomes measured were substance P, prostaglandin E metabolite, mechanical nociceptive threshold, gait analysis, behavior analysis, physical examinations, and intake bloodwork. Results: 20 calves with NCD and 8 healthy calves were enrolled. Prostaglandin E metabolite was significantly higher in calves with NCD than controls. Control calves were more reactive to pressure over the hip than calves with NCD, particularly those treated with meloxicam. Calves with NCD had shorter stride length and slower gait velocity compared to controls. Calves with NCD spent more time lying and more time lying with their head up compared to controls. Calves in the MEL group spent more time lying with their head down compared to PLBO calves. Conclusions: Differences in mechanical nociceptive threshold, gait analysis, and lying behavior possibly indicated the presence of abdominal pain. Differences in head posture between MEL and PLBO calves suggest that calves treated with meloxicam may have been more comfortable. Clinical Relevance: Calves with NCD may experience pain, and treating them with meloxicam may relieve that pain.


  • Open Access

    Pilot study: impacts of cannabinoids from industrial hemp and repeated transportation events on cattle health and immune status

    by Bailey R Fritz, Michael D Kleinhenz, Jason J Griffin, Mikaela M Weeder, Geraldine Magnin, Alyssa A Nelson, Blaine T Johnson, Andrew K Curtis, Johann F Coetzee

    Recent legislative approval of industrial hemp (IH) cultivation has increased interest in the possibility of using IH and IH byproducts in livestock feed. Understanding the therapeutic effects of IH is critical for regulatory decisions and application to the cattle industry. The objective of this pilot study was to describe the effects of IH administration on stress and inflammatory biomarkers and activity in cattle experiencing repeated transportation. Twelve Holstein steers (430 kg, SEM = 3.4; 947 lb, SEM = 7.6) were assigned randomly to treatment sequences (n = 3 per sequence) in a 4 × 4 Latin Square design study (four periods and four treatment sequences). Treatments consisted of one of two drugs (IH or placebo; HEMP, PLBO) and one of two transportation events (transport or control; TRANS, CNTL) during each period so that every steer received all treatment combinations during the study. Industrial hemp was dosed at 5.5 mg/kg cannabidiolic acid (CBDA), with IH or placebo given once by oral bolus immediately prior to the transport or control event. Body weight, accelerometry, kinetic gait analysis, mechanical nociceptive threshold, infrared thermography, complete blood count (CBC), serum biochemistry, blood cortisol, prostaglandin E2 metabolite (PGEM), and serum amyloid A (SAA) were assessed using multiple linear regression. Summary statistics for plasma cannabinoid concentration were generated. There was a drug by transport by time interaction for change in PGEM from baseline (P = 0.03): steers in the HEMP-CNTL group had negative change at 48 h, whereas PLBO-CNTL steers had positive change at 48 h. Both TRANS and CNTL steers had increased lying times in the period immediately after transport. Steers in the TRANS group had greater body weight loss (P <0.0001), neutrophils (P < 0.0001), monocytes (P = 0.04), blood glucose (P < 0.0001), and total protein (P <0.0001) compared to CNTL steers immediately following transport. Cortisol area under the curve values were greater for TRANS versus CNTL steers (P < 0.0001). Lymphocyte concentrations were decreased for TRANS steers compared to CNTL following transport (P < 0.0001). There was a transport by time interaction for SAA (P < 0.0001), with TRANS steers at 24 and 32 h having the greatest SAA concentrations. Further investigation is required to confirm if feeding IH reduces PGEM. Novel outcomes evaluated in this pilot study will assist in design of future transportation trials.

  • Open Access

    Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle

    by Bailey R Fritz, Michael D Kleinhenz, Jason J Griffin, Mikaela M Weeder, Alyssa A Nelson, Andrew K Curtis, Geraldine Magnin, Jonathan Ferm, Roman R Ganta, Johann F Coetzee

    With recent legalization of industrial hemp (IH) production and increased interest in including IH and its byproducts in cattle feed, there is a need to establish the pharmacokinetic profiles of cannabinoids in cattle and guidelines for animal surveillance programs to ensure safety of cattle products entering the food supply. Our group has previously described the pharmacokinetics of cannabidiolic acid (CBDA) and concentrations of other cannabinoids in plasma. In the present study, the plasma cannabinoid concentrations in twelve (12) Holstein steers receiving alfalfa pellet placebo (PLBO), chlortetracycline (CTC) pellets (1.1 mg/kg/d), IH (5.5 mg/kg/d CBDA; HEMP), or a combination of CTC and IH (COMBO) once daily for 63 d were evaluated. Plasma samples were collected every 7 d from day −7 to 77. Eleven cannabinoids were detected above the lower limit of quantification (LLOQ), with the cannabinoid (−)-7-nor-7-carboxy cannabidiol (CBD-7-acid) reaching the highest concentrations. All cannabinoids except CBD-7-acid were below LLOQ by 14 d after final hemp administration. In cattle not receiving IH, CBD-7-acid was detected in multiple steers and timepoints. CBDA was detected in 4 samples (2 steers from each of the PLBO and CTC groups). Both 9-THC and its precursor, THCA, were detected above LLOQ in a singular sample from a steer in the CTC group. These findings suggest that cattle not receiving IH could have detectable concentrations of CBD-7-acid in the blood if cohoused with animals that are exposed to IH. Sample contamination may have been responsible for the detectable 9-THC, THCA, and CBDA concentrations. Based on our results, CBD-7-acid may be a useful tool for screening cattle for IH exposure. However, given the consistent, detectable concentrations in groups not administered IH, a confirmatory test or specific criteria for interpreting CBD-7-acid concentrations would be warranted. These data will help inform decisions regarding surveillance and tolerances for cannabinoid testing in food animals and animal products entering the food supply.

  • Open Access

    Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus)

    by Michael D. Kleinhenz, Darian Davis, Mikaela M. Weeder, Alyssa Leslie, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee

    Gabapentin is used in goats to treat chronic pain associated with lameness. However, pharmacokinetic data and clinical effectiveness trials are lacking. The objective of the study was to describe the pharmacokinetics of gabapentin in goats following a single oral dose. Six Spanish‐crossbred goats were enrolled. Each goat was administered gabapentin at a target dose of 15 mg/kg per os. Serial blood samples were collected out to 60 h post‐gabapentin administration for plasma gabapentin concentration determination. Plasma samples were analyzed for gabapentin concentration using ultra‐high‐pressure liquid chromatography coupled with mass spectroscopy. Individual animal pharmacokinetic outcomes were determined using non‐compartmental analysis. Gabapentin was detectable in the plasma of all goats at 60 h post‐administration. The mean (±SD) Cmax was 2.01 ± 0.62 μg/mL which occurred at 8.47 ± 1.9 h. The mean terminal half‐life (T1/2) and mean resident time were determined to be 8.52 ± 1.8 and 18.7 ± 4.0 h, respectively. This study indicates gabapentin is absorbed from the gastrointestinal tract of goats. Further research is needed to determine an optimal dose for clinical efficacy in goats.


  • Open Access

    Optimal lameness induction model development using amphotericin B in meat goats

    by Mikaela M Weeder, Michael D Kleinhenz, Emily J Reppert, Bailey R Fritz, Abbie V Viscardi, Shawnee R Montgomery, Miriam S Martin, Andrew K Curtis, Alyssa A Leslie, Maria E Lou, et al.

    Lameness continues to be a critical health and welfare concern associated with goat production. Amphotericin B (amp B) is an antimicrobial successful in inducing transient lameness for research purposes previously in livestock animals. The objectives of this study were to (1) identify which of three varying doses of amp B would be most effective in inducing lameness in meat type goats and (2) develop a facial grimace scale for goats. Lameness was produced by an intra-articular injection of amphotericin B into the left hind lateral claw distal interphalangeal joint with either a 5 mg/0.25 mL (high–low, 5 mg of amphotericin B in a volume of 0.25 mL), 5 mg/0.5 mL (high–high, 5 mg of amphotericin B in a volume of 0.5 mL), or a 2.5 mg/0.25 mL (low–low, 2.5 mg of amphotericin B in a volume of 0.25 mL). A saline treatment of 0.5 mL was used as control (0.9% sterile saline solution). Lameness response was analyzed by infrared thermography (IRT) at the induced joint, mechanical-nociception threshold (MNT), visual lameness scoring (VLS), a visual analogue scale (VAS), kinetic gait analysis (KGA), plasma cortisol (CORT), substance P (Sub P), and behavior scoring. The IRT and MNT values differed by timepoint (P ≤ 0.0001). Results from VLS showed the HL treatment was the most effective at inducing lameness (6/6 goats became lame compared to HH 4/6 and LL 2/6). At 24, 48, and 72 h, VAS scores were significantly higher when comparing HL to all other treatment groups (P = 0.0003). Both behavior observers (1 and 2) reported a significant time effect (P = 0.05), with goats exhibiting more facial grimacing at 24 h post-lameness induction. From these data, an optimal dose for a repeatable lameness induction model in goats was aquired. An effective Goat Grimace Scale (GGS) was also developed to evaluate pain responses in goats.


  • Open Access

    Delivering an Immunocastration Vaccine via a Novel Subcutaneous Implant

    by Andrew K. Curtis, Douglas E. Jones, Michael Kleinhenz, Shawnee Montgomery, Miriam Martin, Mikaela Weeder, Alyssa Leslie, Balaji Narasimhan, Sean Kelly, Drew R. Magstadt, et al.

    Immunocastration relies on the vaccine-mediated stimulation of an immune response to gonadotropin-releasing hormone (GnRH) in order to interrupt spermatogenesis. This approach offers a less painful alternative to traditional castration approaches but the current, commercially available options require multiple doses of vaccine to maintain sterility. Thus, a series of pilot studies were conducted to determine the feasibility of a single-dose immunocastration vaccine implant. These five studies utilized a total of 44 Holstein bulls to determine the optimal vaccine composition and validate the ability of a stainless-steel subcutaneous implant to deliver a vaccine. Outcome measures included the duration of implant retention, scrotal dimensions and temperature, implant site temperature, anti-GnRH antibodies, and serum testosterone concentration. Over the course of several studies, anti-GnRH antibodies were successfully stimulated by vaccine implants. No significant treatment effects on scrotal dimensions or testosterone were detected over time, but changes in spermatogenesis were detected across treatment groups. Results indicate that a single-dose implantable immunocastration vaccine elicits a humoral immune response and could impact spermatogenesis in bulls. These findings provide opportunities for the refinement of this technology to improve implant retention over longer periods of time. Taken together, this approach will offer producers and veterinarians an alternative to physical castration methods, to improve animal welfare during routine livestock management procedures.


  • Open Access

    The effect of breed, sex, and oral meloxicam administration on pain biomarkers following hot-iron branding in Hereford and Angus calves

    by Miriam S Martin, Michael D Kleinhenz, Lily N Edwards-Callaway, Terry E Engle, Octavio Guimaraes, David W Schafer, Shawnee R Montgomery, Andrew K Curtis, Mikaela M Weeder, Devin R Jacobs, et al.

    Hot-iron branding uses thermal injury to permanently identify cattle causing painful tissue damage. The primary objective was to examine the physiological and behavioral effects of oral meloxicam (MEL), compared to a control, administered at the time of hot-iron branding in Angus and Hereford steers and heifers. The secondary objectives were to investigate breed and sex effects on pain biomarkers. A total of 70 yearlings, consisting of 35 heifers and 35 steers (Angus, Hereford, or Angus × Hereford), were enrolled in the study. Animals were blocked by sex, randomized across weight, and assigned to receive MEL (1 mg/kg) or a placebo (CON). Biomarkers were assessed for 48 h after branding and included infrared thermography (IRT), mechanical nociceptive threshold (MNT), accelerometry and a visual analog scale (VAS), and serum cortisol and prostaglandin E2 metabolites (PGEM). Wound healing was assessed for 12 wk. Hair samples to quantify cortisol levels were taken prior to and 30 d post-branding. Responses were analyzed using repeated measures with calf nested in treatment as a random effect, and treatment, time, treatment by time interaction, breed, and sex as fixed effects. There was a treatment by time interaction for PGEM (P < 0.01) with MEL having lower values than CON at 6, 24, and 48 h (MEL: 18.34 ± 3.52, 19.61 ± 3.48, and 22.24 ± 3.48 pg/mL, respectively; CON: 32.57 ± 3.58, 37.00 ± 3.52, and 33.07 ± 3.48 pg/mL; P < 0.01). MEL showed less of a difference in maximum IRT values between the branded (2.27 ± 0.29 °C) and control site (3.15 ± 0.29 °C; P < 0.01). MEL took fewer lying bouts at 0–12 h (4.91 bouts ± 0.56) compared with CON (6.87 bouts ± 0.55; P < 0.01). Compared with Hereford calves, Angus calves exhibited greater serum but lower hair cortisol, greater PGEM, more lying bouts, and less healed wound scores at 3, 4, and 5 wk. Compared with heifers, steers exhibited lower PGEM, lower branding site and ocular IRT, higher MNT, and lower plasma meloxicam levels. Steers spent more time lying, took more lying bouts and had greater VAS pain, and more healed wound scores at 5 wk than heifers. Meloxicam administration at branding reduced branding and control site temperature differences and reduced lying bouts for the first 12 h. Breed and sex effects were observed across many biomarkers. Changes from baseline values for IRT, MNT, lying time, step count, VAS pain, and wound scoring all support that branding cattle is painful. Hot-iron branding uses thermal injury to permanently identify cattle causing painful tissue damage. The primary objective was to examine the effects of oral meloxicam (MEL), compared with a control, administered at the time of hot-iron branding in Angus and Hereford steers and heifers. The secondary objectives were to investigate breed and sex effects on pain biomarkers. A total of 70 yearlings, consisting of 35 heifers and 35 steers (Angus, Hereford, or Angus × Hereford), were enrolled. Animals were assigned to receive MEL or a placebo. Changes from baseline values for infrared thermography (IRT), mechanical nociceptive threshold, lying time, step count, visual analog scale score, and wound scoring all support that hot-iron branding cattle is painful and investigation into analgesic strategies is needed. MEL administration reduced IRT differences from the branding and control site and reduced lying bouts. Breed and sex effects were observed across a wide range of biomarkers and should be considered in future pain studies. The practicality of administering a nonsteroidal anti-inflammatory drug once at the time of branding is attractive. However, a multimodal approach using a combination of analgesics or longer acting analgesic option warrants further investigation to alleviate pain and discomfort caused by hot-iron branding.